Key Takeaways
- • SOAR Bio, a life sciences venture studio based at the Children's National Research and Innovation Campus in Washington, D.C., was awarded $600,000 through the District's new Technology Ecosystem Fund, announced by Mayor Muriel Bowser on October 19, 2026.
- • The funding will expand SOAR Bio's studio to support the incubation and launch of five D.C.-based life sciences companies, according to the publisher's report.
- • The Technology Ecosystem Fund was established in 2026 as part of Mayor Bowser's Growth Agenda; its inaugural awards also went to New Majority Ventures and Plug and Play.
- • SOAR Bio is positioned as Washington, D.C.'s first life sciences venture studio, building companies from internally developed or in-licensed intellectual property using small, experienced teams and milestone-tied spending.
- • The award comes as D.C.'s life sciences sector raised $426 million in venture capital in 2025, per the mayor's State of DC Tech 2026 report.
Summary
SOAR Bio, a life sciences venture studio based at the Children's National Research and Innovation Campus in Washington, D.C., has been awarded $600,000 through the District's new Technology Ecosystem Fund. Mayor Muriel Bowser announced the award on October 19, 2026, at an event celebrating the 11th annual DC Startup and Tech Week. SOAR Bio will use the funding to expand its venture studio and support the incubation and launch of five D.C.-based life sciences companies.
The Technology Ecosystem Fund was established in 2026 as part of Mayor Bowser's Growth Agenda and supports programs that help early-stage companies start, grow and scale in D.C. Alongside SOAR Bio, its inaugural awards went to accelerator programs New Majority Ventures and Plug and Play. The award comes as the District works to grow its life sciences sector, which raised $426 million in venture capital in 2025, according to the mayor's State of DC Tech 2026 report.
SOAR Bio's Founding Partner, Murat Kalayoglu, MD, PhD, said the grant lets the studio and its portfolio companies put more resources into experiments and people without giving up equity. The funding will support three priorities: turning Greater Washington's scientific discoveries into D.C.-based companies, training the next generation of life sciences leaders, and providing scientific and commercial guidance to researchers and institutions across the region. SOAR Bio currently has three portfolio companies, Lysin, Klarify Bio and Nightwatch, spanning therapeutics, devices and diagnostics.
The studio differs from the traditional biotech model by building its own companies from the ground up, starting with internally developed intellectual property or early-stage technology in-licensed from outside institutions. Each venture is guided by a small, experienced management team that works across multiple portfolio companies and uses AI in research and operations, with spending tied to scientific milestones. Kalayoglu told BioBuzz he believes this capital-efficient approach could become a model for biotech company building nationally. He cited the region's NIH funding concentration, talent and more affordable space as advantages relative to other leading hubs. Immediate priorities include generating data to establish scientific proof of concept, recruiting and training CEO Fellows, and strengthening the scientific team.
SOAR Bio will host a session, The DC Advantage, with BioBuzz on October 21, 2026, at the Children's National Research & Innovation Campus as part of DC Startup & Tech Week. The program features leaders from Children's National, Virginia Tech, Georgetown University, the D.C. Office of the Deputy Mayor for Planning and Economic Development, and ARPA-H.
The Technology Ecosystem Fund was established in 2026 as part of Mayor Bowser's Growth Agenda and supports programs that help early-stage companies start, grow and scale in D.C. Alongside SOAR Bio, its inaugural awards went to accelerator programs New Majority Ventures and Plug and Play. The award comes as the District works to grow its life sciences sector, which raised $426 million in venture capital in 2025, according to the mayor's State of DC Tech 2026 report.
SOAR Bio's Founding Partner, Murat Kalayoglu, MD, PhD, said the grant lets the studio and its portfolio companies put more resources into experiments and people without giving up equity. The funding will support three priorities: turning Greater Washington's scientific discoveries into D.C.-based companies, training the next generation of life sciences leaders, and providing scientific and commercial guidance to researchers and institutions across the region. SOAR Bio currently has three portfolio companies, Lysin, Klarify Bio and Nightwatch, spanning therapeutics, devices and diagnostics.
The studio differs from the traditional biotech model by building its own companies from the ground up, starting with internally developed intellectual property or early-stage technology in-licensed from outside institutions. Each venture is guided by a small, experienced management team that works across multiple portfolio companies and uses AI in research and operations, with spending tied to scientific milestones. Kalayoglu told BioBuzz he believes this capital-efficient approach could become a model for biotech company building nationally. He cited the region's NIH funding concentration, talent and more affordable space as advantages relative to other leading hubs. Immediate priorities include generating data to establish scientific proof of concept, recruiting and training CEO Fellows, and strengthening the scientific team.
SOAR Bio will host a session, The DC Advantage, with BioBuzz on October 21, 2026, at the Children's National Research & Innovation Campus as part of DC Startup & Tech Week. The program features leaders from Children's National, Virginia Tech, Georgetown University, the D.C. Office of the Deputy Mayor for Planning and Economic Development, and ARPA-H.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.